Description

Insulin Icodec is a novel insulin analog engineered to provide ultra-long duration of action through reversible binding to serum albumin. Unlike conventional insulins that require frequent administration, Insulin Icodec is specifically designed to maintain prolonged activity, enabling once-weekly administration in experimental settings. With a purity of 95.00%, and manufactured by a GMP-compliant supplier, Insulin Icodec offers consistent quality and reliability for advanced laboratory research.

The unique structural modification of Insulin Icodec allows it to exhibit strong but reversible interaction with albumin, thereby delaying absorption and clearance from plasma. This mechanism makes it highly valuable for type 2 diabetes research, where it serves as a model compound to investigate novel long-acting insulin therapies.

Researchers working with Insulin Icodec can study pharmacokinetics, glucose-lowering effects, insulin-receptor interactions, and comparative profiles versus existing insulin formulations. Beyond glycemic control, Insulin Icodec also provides opportunities to explore metabolic outcomes, patient adherence models, and safety markers related to sustained insulin action.

The product is offered in wholesale and retail quantities, ensuring flexibility for laboratories of different scales. With strict GMP manufacturing standards, every batch of Insulin Icodec maintains reproducibility, stability, and traceable quality documentation for professional use.

Product Specifications

Mechanism of Action & Research Applications

Insulin Icodec is designed as a long-acting insulin analog with improved pharmacokinetic properties compared to daily insulin formulations. Its primary mechanism is based on enhanced reversible albumin binding, which delays distribution and clearance. This feature creates a prolonged plasma half-life, enabling weekly administration in research settings.

In type 2 diabetes research, Insulin Icodec provides a valuable tool to study:

• Glucose metabolism regulation – how extended insulin activity modulates blood glucose levels over several days.

• Insulin-receptor signaling – the analog can be compared to standard insulin to analyze receptor affinity and downstream signaling pathways.

• Pharmacodynamics (PD) & Pharmacokinetics (PK) – extended half-life models are studied to improve drug adherence strategies.

• Safety and tolerability markers – research includes examining hypoglycemia risk, immunogenicity, and long-term safety signals.

• Patient adherence models – weekly insulin injection protocols may significantly reduce treatment burden, which is studied in preclinical frameworks.

Additionally, Insulin Icodec contributes to the development of next-generation basal insulin analogs, aiming to optimize efficacy, safety, and patient compliance.

Development & Formulation Notes

Insulin Icodec represents a new class of long-acting basal insulin analogs. Unlike standard insulins, its structure is optimized for albumin binding without compromising receptor activation. This molecular engineering allows Insulin Icodec to be stable in plasma for days, minimizing the need for frequent injections.

Formulation stability is supported by lyophilization, ensuring extended shelf life and robust handling during transport. As a research-grade compound, Insulin Icodec is produced under strict GMP conditions, guaranteeing batch-to-batch reproducibility, traceability, and compliance with global quality standards.

This product is distributed in secure packaging, tailored for both small-scale laboratory use and bulk supply for research institutions. Documentation, including Certificates of Analysis (CoA), is available to support laboratory needs.

Through its unique design, Insulin Icodec is positioned as a model compound in diabetes research, allowing investigation into next-generation therapies that aim to improve patient adherence and treatment outcomes.

Side Effects (For Research Reference Only)

In research models, potential side effects of Insulin Icodec may include:

• Hypoglycemia (low blood glucose)

• Injection site reactions

• Weight gain trends observed with prolonged insulin exposure

• Rare immunogenic responses in preclinical studies

These effects are provided for reference only in controlled experimental research and are not indicative of clinical or therapeutic usage.

Disclaimer

Insulin Icodec is supplied strictly for laboratory research use only. It is not intended for human consumption, medical use, or therapeutic applications. All handling should be performed by qualified professionals in appropriate research facilities.

Logistics & Packaging

• Packaging: Securely sealed vials, available in multiple research sizes (small-scale and bulk).

• Labeling: Each vial includes product name, CAS number, batch number, purity, and storage instructions.

• Transport: Shipped under temperature-controlled conditions to maintain product stability.

• Storage: Recommended at –20°C, avoid repeated freeze-thaw cycles.

• Wholesale & Retail Supply: Available in flexible quantities to accommodate different laboratory requirements.

Keywords

 CAS 1188379-43-2, Insulin Icodec analog, long-acting insulin analog, albumin-binding insulin, type 2 diabetes research, basal insulin analog, GMP insulin supplier, Insulin Icodec wholesale, research insulin analog